Several specific designs can be utilised to assess dose response, which fall broadly into four categories, namely free titration, forced titration and dose escalation, parallel dose response, and dose reduction studies.
Both drugs exhibited parallel dose-dependent inhibition of proliferation in non-irradiated and irradiated cells.
In most cases, our assumption that genes within a pathway were expressed in a parallel dose response was supported by the data.
The trial was performed as a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel, dose-ranging study between 2001 and 2006.
Increased O2 - in wild type cells exposed to NAC was accompanied by a parallel dose-dependent increase in the fraction of cells with visible buds.
Study designs that allow a better understanding of the pharmacokinetic pharmacodynamic relationship are encouraged (Table 1, CS2); however, usually some Phase II parallel dose-finding studies are still required for new drugs.
Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and in parallel dose-response studies, b) single doses of the weak agonists identical to one of five doses from the dose-response studies, and c) a single dose of the negative test substance.
Part B was a parallel dose-finding and dose-schedule study in which patients were randomised in a 1 : 1 : 1 : 1 ratio to receive one dose of darbepoetin alfa (3.0, 5.0, 7.0 or 9.0 m.c.g. kg−1) once every 2 weeks or epoetin alfa 40 000 U wk−1.
FK866 caused a partial reduction in total AMPK levels at the highest dose used, but, at a same time, a parallel dose-dependent increase of the phosphorylation of its Thr-172 and of its bona fide target ACC (Acetyl-CoA Carboxylase) (Fig. 3a), indicating a significant activation of AMPK.
Based on the above, we conducted an open-label, parallel-dose escalation study evaluating the combinations of dalotuzumab with MK-0752 MK-2206206 in solid tumours with expansion cohorts in biomarker-positive ovarian and colon cancer patients of these phase I doublets at their RP2Ds, and an additional expansion cohort of ovarian cancer with dalotuzumab and ridaforolimus.
However, a classical parallel group dose response trial investing several doses including at least one ineffective dose is not possible due to ethical considerations.
